Rothschild Capital Partners Exits Position in Pacific Biosciences of California (PACB)

Pacific Biosciences of California (PACB) : Rothschild Capital Partners has sold out all of its stake in Pacific Biosciences of California during the most recent quarter, according to the disclosure filed by the company on Jul 26, 2016 with the SEC. The investment management company has sold out 10,750 shares of Pacific Biosciences of California which is valued at $87,075.

Other Hedge Funds, Including , Strs Ohio reduced its stake in PACB by selling 26,000 shares or 58.82% in the most recent quarter. The Hedge Fund company now holds 18,200 shares of PACB which is valued at $147,420. Meeder Asset Management Inc added PACB to its portfolio by purchasing 176 company shares during the most recent quarter which is valued at $1,399.First American Bank reduced its stake in PACB by selling 845 shares or 2.99% in the most recent quarter. The Hedge Fund company now holds 27,420 shares of PACB which is valued at $217,989. Pacific Biosciences of California makes up approx 0.02% of First American Bank’s portfolio.Trellus Management Company boosted its stake in PACB in the latest quarter, The investment management firm added 63,600 additional shares and now holds a total of 225,000 shares of Pacific Biosciences of California which is valued at $1,779,750. Pacific Biosciences of California makes up approx 4.02% of Trellus Management Company’s portfolio.

Pacific Biosciences of California closed down -0.05 points or -0.58% at $8.55 with 11,23,034 shares getting traded on Friday. Post opening the session at $8.53, the shares hit an intraday low of $8.29 and an intraday high of $8.63 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pacific Biosciences of California reported $-0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 21, 2016. Analyst had a consensus of $-0.24. The company had revenue of $19.10 million for the quarter, compared to analysts expectations of $17.70 million. The company’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.

Many Wall Street Analysts have commented on Pacific Biosciences of California. Pacific Biosciences of California was Initiated by CL King to “Buy” on Jun 27, 2016.

Pacific Biosciences of California Inc. designs develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company’s Single Molecule Real-Time (SMRT) technology its products enable de novo genome assembly to finish genomes in order to more fully identify annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule real-time detection of biological processes. Based on its SMRT technology the Company introduced the PacBio RS II System to address many of the limitations.

Leave a Reply

Pacific Biosciences of California - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacific Biosciences of California. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.